TNF-alpha inhibitors
PreclinicalSmall molecule
TNF-alpha inhibitors is one of 14 small molecule programs targeting Papilloma. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Papilloma
#DrugCompanyPhaseTrials
1Vistide
GileadApproved
Celebrex
PPhiladelphia Eye Associates
Approved
HPV Vaccine
SShanghai Zerun Biotechnology Co.,Ltd
Phase 3
Taxol
TevaPhase 2
Keytruda
Merck & Co.Phase 2
Recombinant Human GM-CSF
EEastern Cooperative Oncology Group
Phase 3
Gardasil9
Merck & Co.Phase 3
Paraplatin
AAvyxa
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Nonavalent HPV Vaccine
XXiamen University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Papilloma1 trial
Rheumatoid Arthritis1 trial
Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes
Terminated·—·Phase 4·NCT02236481·41 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TNF-alpha inhibitors. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMedical University of Vienna